ANKYLOSING spondylitis (AS)
sufferers in the UK have received
new guidance from the National
Institute for Health and Care
Excellence (NICE) around the use of
secukinumab (Cosentyx, Novartis),
registered in the UK in May 2016.
The drug has been registered
in Australia since Jan last year
and funded from Sep last year,
Authority Required on the PBS with
a cost to taxpayers of $1,763.70 for
two units with five repeats allowed.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Aug 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.